- 1
- 2

A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2

3

4	
5	Authors: Kang Wang ¹ ^{\$} , Yunlong Cao ³ ^{\$} , Yunjiao Zhou ² ^{\$} , Jiajing Wu ^{4,§} , Zijing Jia ¹ ^{\$} , Yaling Hu ⁵ ^{\$} ,
6	Ayijiang Yisimayi ³ , Wangjun Fu ¹ , Lei Wang ¹ , Pan Liu ¹ , Kaiyue Fan ¹ , Ruihong Chen ^{1,6} , Lin
7	Wang ⁵ , Jing Li ⁵ , Yao Wang ³ , Xiaoqin Ge ⁵ , Qianqian Zhang ² , Jianbo Wu ² , Nan Wang ¹ , Wei Wu ² ,
8	Yidan Gao ² , Jingyun Miao ⁷ , Yinan Jiang ⁷ , Lili Qin ⁷ , Ling Zhu ¹ , Weijin Huang ⁵ , Yanjun Zhang ⁹ ,
9	Huan Zhang ⁸ , Baisheng Li ⁸ , Qiang Gao ⁵ , Xiaoliang Sunney Xie ³ *, Youchun Wang ⁴ *, Qiao
10	Wang ² * and Xiangxi Wang ^{1,6} *
11	
12	Affiliation:
13	¹ CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute
14	of Biophysics, Chinese Academy of Sciences, Beijing 100101, China
15	² Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical
16	Sciences; Shanghai Institute of Infectious Disease and Biosecurity; Shanghai Medical College,
17	Fudan University, Shanghai 200032, China
18	³ Beijing Advanced Innovation Center for Genomics (ICG), Biomedical Pioneering Innovation
19	Center (BIOPIC), School of life Science, Peking University, Beijing 100091, China
20	⁴ Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product
21	Control, National Institutes for Food and Drug Control (NIFDC), Beijing 102629, China
22	⁵ Sinovac Biotech Ltd, Beijing, China
23	⁶ Guangzhou Laboratory, Guangzhou, Guangdong, China, 510320
24	⁷ Acrobiosystems Inc, Beijing, China
25	⁸ Guangdong Provincial Center for Disease Control and Prevention
26	⁹ Department of Microbiology, Zhejiang Provincial Center for Disease Control and Prevention,
27	Hangzhou, China
28 29 30	*Correspondence to: X.W. (Email: xiangxi@ibp.ac.cn) or Q.W. (Email: wangqiao@fudan.edu.cn) or Y.W. (Email: wangyc@nifdc.org.cn) or X.S.X. (Email: sunneyxie@biopic.pku.edu.cn)

31 [§] These authors contributed equally to this work.

32

33 Abstract: (~150 words)

Emergence of variants of concern (VOC) with altered antigenic structures and waning 34 humoral immunity to SARS-CoV-2 are harbingers of a long pandemic. Administration 35 of a third dose of an inactivated virus vaccine can boost the immune response. Here, 36 we have dissected the immunogenic profiles of antibodies from 3-dose vaccinees, 2-37 dose vaccinees and convalescents. Better neutralization breadth to VOCs, expeditious 38 recall and long-lasting humoral response bolster 3-dose vaccinees in warding off 39 COVID-19. Analysis of 171 complex structures of SARS-CoV-2 neutralizing 40 antibodies identified structure-activity correlates, revealing ultrapotent, VOCs-41 resistant and broad-spectrum antigenic patches. Construction of immunogenic and 42 mutational heat maps revealed a direct relationship between "hot" immunogenic sites 43 and areas with high mutation frequencies. Ongoing antibody somatic mutation, 44 memory B cell clonal turnover and antibody composition changes in B cell repertoire 45 driven by prolonged and repeated antigen stimulation confer development of 46 monoclonal antibodies with enhanced neutralizing potency and breadth. Our findings 47 rationalize the use of 3-dose immunization regimens for inactivated vaccines. 48

- 49
- 50
- 51

52 **One sentence summary**

A third booster dose of inactivated vaccine produces a highly sifted humoral immune
response *via* a sustained evolution of antibodies capable of effectively neutralizing
SARS-CoV-2 variants of concern.

- 56
- 57
- 58
- 59

60 Main Text:

The ongoing coronavirus disease 2019 (COVID-19) pandemic caused by severe 61 acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has lasted for one and a 62 half years, resulting in an unprecedented public health crisis with over 4 million 63 deaths globally. Progress in halting this pandemic seems slow due to the emergence 64 of variants of concern (VOC), such as the B.1.1.7 (Alpha), B.1.351 (Beta), P.1 65 (Gamma, also known as B.1.1.28.1) and more recent B.1.617.2 (Delta), that appear 66 to be high transmissible and more resistant to neutralizing antibodies (1-4). While 67 several types of COVID-19 vaccines are being deployed at a large scale, new variants 68 are thought to be responsible for re-infections, either after natural infection or after 69 vaccination, as observed in Brazil and the United States, respectively (5, 6). Closely 70 correlated with these, a general decrease in immune protection against SARS-CoV-71 72 2 variants within 6-12 months after the primary infection or vaccination is also observed (6-8). The prospect of genetic recombination and antigenic drift in recent 73 SARS-CoV-2 variants together with non-uniform immune protections arising from 74 heterogeneously waning humoral immunity in COVID-19 convalescent or 75 76 vaccinated individuals, point to the potential risks of a long-term pandemic that could 77 endanger the global human health, diminishing social, economic and outdoor leisure activities. A plausible approach to solving this problem is the administration of a 78 third dose of the vaccine somewhere between 6 and 12 months after the 2nd dose of 79 vaccination for enhancing and prolonging the protection. However, not much is 80 known about the immunogenic features of such a booster dose of a COVID-19 vaccine. 81 In addition, there are large gaps in our understanding about correlating immunogenic 82 findings from surrogate endpoints to gauge vaccine efficacy. 83

84

The CoronaVac, a 2-dose β -propiolactone-inactivated vaccine against COVID-19, has been approved for emergency use by the World Health Organization (9, 10). In human clinical trials (phase I/II, registration number: NCT04352608), a subgroup with a 3-dose immunization schedule at months 0, 1, 7 was also included. To evaluate immune features, we recruited 22 COVID-19 convalescents, 6 healthy participants (SARS-CoV-2 negative, confirmed by RT-PCR) and 38 volunteers who received either 2 or 3 doses of the Coronavac vaccine for blood donation. The volunteers
ranged from 16 to 69 years old (median 33); 30 (45.5%) were men and 36 (54.5%)
were women. None of the volunteers recruited for vaccination was infected by
SARS-CoV-2 prior to the study. Blood samples from convalescents and vaccinees
collected 1.3 months after infection and the indicated times after vaccination were
used in this study, respectively, to compare humoral immune responses elicited
against circulating SARS-CoV-2 variants.

98

99 Neutralizing antibodies (NAbs) are a major correlate of protection for many viruses, including SARS-CoV-2, and have also provided the best correlate of vaccine 100 efficacy. Several types of SARS-CoV-2 neutralization assays have been described 101 using either live SARS-CoV-2 or a pseudo-typed reporter virus carrying SARS-CoV-102 2 spike protein (S). Both types of assays could yield reproducible neutralizing titers, 103 with the pseudo-typed virus neutralization assay exhibiting higher sensitivity (11, 104 12). Neutralizing activity of plasma samples from 66 participants was measured 105 against WT, B.1.351, P.1 and B.1.617.2 using live SARS-CoV-2 and VSV-106 107 pseudoviruses with the S from WT, B.1.1.7, P.1 variants and SARS-CoV (Fig. 1). 108 The geometric mean half-maximal neutralizing titers (GMT NT₅₀) against live SARS-CoV-2 in plasma obtained from convalescents and from vaccinees (4 weeks 109 after the final vaccination) suggest an approximately 60% higher neutralizing 110 activity against WT after 3-dose inoculation when compared with 2-dose 111 administration, and 20% higher than those from convalescents (Fig. 1A). 112 Interestingly, for the samples from the convalescents, 2-dose and 3-dose vaccinees, 113 neutralizing titers against B.1.351 were, on average, 7.7-fold, 5.7-fold and 3.0-fold 114 reduced, respectively, compared with WT (Fig. 1A). Similarly, fold decreases in 115 116 neutralization ID₅₀ titers against P.1 and B.1.617.2 for the three cohorts were 5.3, 4.3 and 3.1, and 5.3, 3.7 and 2.3, respectively (Fig. 1A). Overall, plasma of the 3-dose 117 vaccinees displayed minimal reduction in neutralization titers against several 118 authentic VOCs compared to the convalescents and 2-dose vaccinees (Fig. 1A). 119 Remarkably, ~41% (9/22) and 50% (6/12) samples from the convalescents and 2-120 dose vaccinees, respectively, failed to reach 50% neutralization at a plasma dilution 121

122 of 1: 10, with $\sim 14\%$ (3/22) and 16% (2/12) showing a near ineffectiveness in 123 neutralizing B.1.351 in vitro (Fig. 1A). By contrast, only 1 out of 14 samples from the 3-dose vaccinees exhibited a weak neutralizing titer below 10 (Fig. 1A). 124 Importantly, the 3-dose vaccinees showed over 2.5-fold higher neutralizing potency 125 against B.1.617.2 than the convalescents and 2-dose vaccinees (Fig. 1A). The GMT 126 NT₅₀ values measured by a VSV-pseudovirus with the WT S were 840, 660 and 1,176 127 for convalescents, 2-dose and 3-dose vaccinees, respectively, which were 8-10-fold 128 greater than those determined by live WT SARS-CoV-2 (Fig. 1A, 1B), confirming 129 higher sensitivity of pseudovirus-based assays in determining neutralizing titers. In 130 line with the results of live SARS-CoV-2 neutralization assay, the mean fold decrease 131 in the neutralization of B.1.1.7 relative to the WT was 2.8-fold for convalescents, 132 133 2.2-fold for 2-dose vaccinees and 1.7-fold for 3-dose vaccinees (Fig. 1B). Similarly, plasma from convalescents, 2-dose and 3-dose vaccinees exhibited a 4.5-fold, 2.9-134 fold and 2.4-fold reduction, in NAb titers against P.1, respectively, when compared 135 to the WT (Fig. 1B). These results reveal that a third-dose boost of inactivated 136 vaccine leads to enhanced neutralizing breadth to SARS-CoV-2 variants, bolstering 137 the potential to ward off VOCs effectively when compared to convalescent plasma. 138 139 Of note, neither vaccination nor SARS-CoV-2 infection boosts distinct neutralizing potency against SARS-CoV, presumably due to the relatively far phylogenic 140 relationship (Fig. 1B). 141

142

To seek information on potential binding-neutralization correlates, the abilities of 143 antibodies present in plasma to bind the receptor-binding domain (RBD), N-terminal 144 domain (NTD), S-trimer and nucleoprotein (N) from SARS-CoV-2 and its variants 145 were measured by enzyme-linked immunosorbent assay (ELISA). As expected, all 146 147 COVID-19 convalescents and vaccinees exhibited high anti-RBD, anti-NTD, anti-S and anti-N titers for SARS-CoV-2 variants, but weak antibody reactivity to SARS-148 CoV (Fig. 1C and fig. S1). Unexpectedly, the amount of N-specific IgG elicited by 149 2-dose and 3-dose vaccination schedules was 2-6-fold lower than those of 150 convalescents, and 2-6-fold lower than the antibodies targeting S or RBD in 151 vaccinees, reflecting distinct serological profiles (Fig. 1C and fig. S1). Overall 152

plasma neutralizing activity against the WT was substantially correlated with anti-S and anti-RBD binding titers in ELISA. However, only marginal correlates between binding and neutralization potency were established for VOCs (fig. S2). In spite of this, a 3-dose administration elicits a broader range of antibody binding activities to VOCs with minimal decreasing folds than those of 2-dose vaccination and convalescents (Fig. 1D and fig. S2).

159

To evaluate the nature of humoral immune response elicited by a booster dose of 160 CoronaVac, the S-specific IgA, IgM and IgG titers and neutralizing activities against 161 SARS-CoV-2 variants were monitored before and 4 weeks after the third 162 immunization. S-specific IgM and IgA titers were generally lower and were not 163 significantly boosted in response to the third-dose vaccination (Fig. 1E). Similar to 164 most convalescents (2), approximately 80~90% of both anti-S IgG and NAb titers 165 against the WT waned 6 months after the second vaccination (13), while the third-166 dose administration of CoronaVac boosted these titers by ~20-fold at 4 weeks post 167 vaccination (Fig. 1E and F). Significantly, vaccinees 6 months after the second 168 immunization did not have detectable in vitro neutralizing activities against B.1.351, 169 170 P.1 and B.1.617.2, while all vaccinees exhibited a robust recall humoral response to efficiently neutralize circulating variants post the third-dose vaccination (Fig. 1E and 171 F). To further characterize the expeditiousness, longevity and immunological 172 kinetics of recall response stimulated by the third-dose immunization, neutralizing 173 potencies at days 0, 7, 14, 28, 90 and 180 post the third-dose vaccination were 174 determined (Fig. 1G and H). Remarkably, NAb titer surged by ~8-fold (from 7 to 53) 175 at week 1, peaked by ~25-fold increase (up to 177) at week 2 after the 3rd-booster 176 177 and slowly decreased over time (Fig. 1G). Notably, NAb titer was maintained at around 60 on 180 days post the 3rd-booster, comparable to the high level of NAb titer 178 elicited by the 2-dose administration (Fig. 1H). Taken together, these serological 179 results reveal a third-dose booster can elicit an expeditious, robust and long-lasting 180 recall humoral response. 181

182

183 The molecular mechanism underlying these potent, broad and durative antibody

responses elicited by a third-dose booster 6 months after the administration of the 184 185 second dose of the vaccine, might involve ongoing antibody somatic mutation and evolution of antibody by affinity maturation through prolonged and repeated antigen 186 stimulation (14, 15). Although circulating antibodies derived from plasma cells wane 187 over time, long-lived immune memory can persist in expanded clones of memory B 188 cells (16). Thereby, we used flow cytometry to sort the SARS-CoV-2 S-trimer-189 specific memory B cells from the blood of seven selected CoronaVac vaccinees, 190 including four samples from 3-dose vaccinees and three samples from 2-dose 191 192 vaccinees (Fig. 2A and fig. S3). The averaged percentage of S-binding memory B cells in 3-dose vaccinees was substantially greater than those in 2-dose vaccinees 193 (Fig. 2A and fig. S3). Due to differences in labeling strategies employed for sorting 194 SARS-CoV-2-specific B cells, the above percentage of memory B cells was not 195 directly comparable with those reported in naturally infected individuals and in 196 mRNA vaccinated individuals. The gated double-positive cells were single cell 197 sorted and immunoglobulin heavy (IGH; IgG isotype) and light (IGL or IGK) chain 198 genes were amplified by nested PCR. Overall, we obtained 422 and 132 paired heavy 199 200 and light chain variable regions from S-binding IgG⁺ memory B cells from four 3dose and three 2-dose vaccinees, respectively (Fig. 2B and fig. S4). Surprisingly, 201 expanded clones of cells comprised 45-61% of the overall S-binding memory B 202 compartment in 3-dose vaccinees, which is approximately 2-fold higher than those 203 in COVID-19 convalescents and in mRNA or 2-dose vaccinated individuals (Fig. 2B 204 and C). When compared to 2-dose vaccinees, the increase in the number of persistent 205 clones and various clonal compositions in 3-dose vaccinated group suggested an 206 ongoing clonal evolution (Fig. 2B and C). Shared antibodies with the same 207 208 combination of IGHV and IGLV genes in 3-dose vaccinees comprised ~20% of all the clonal sequences. Similar to natural infection and mRNA vaccination (2, 14, 16), 209 IGHV3-30, IGHV3-53 and IGHV1-69 remained significantly over-represented in 3-210 dose vaccinees (fig. S5). Meanwhile, notable differences in the frequency of human 211 V genes between 3-dose vaccinated and the other two groups were observed as well 212 (fig. S5). In 3-dose vaccinees, IGHV3-21, IGHV4-39 and IGHV7-4-1 were largely 213 abundant, but IGHV5-51, IGHV3-66 and IGHV1-2 were significantly scarce when 214

compared to the other two groups (fig. S5), indicative of memory B cell clonal 215 216 turnover. Notably, large-scale, single-cell sequencing datasets generated from two cohorts of 2-dose, 3-dose vaccinees and a group of convalescents revealed no distinct 217 preference in the frequency of V genes at total B cell repertoire level (fig. S6), 218 suggesting that a large abundance of antibodies with low expression or affinities exist 219 in B cells. Additionally, the number of nucleotide mutations in the V gene in 3-dose 220 vaccinees is higher than those in both 2-dose vaccinees and naturally infected 221 222 individuals assayed after 1.3 and 6.2 months, but slightly lower than those in 223 convalescent individuals 1 year after infection (Fig. 2D), revealing ongoing somatic hypermutation of antibody genes. There was no significant difference in the length 224 of the IgG CDR3 between vaccinated (either mRNA or inactivated) and convalescent 225 (after 1.3 or 6.2 or months) groups (fig. S7). These results reveal that a third-dose 226 booster 6 months after the second vaccination elicits an enhanced and anamnestic 227 immune response, which is led by clonal evolution of memory B cell and ongoing 228 antibody somatic mutations, resulting in enhanced neutralizing potency, breadth and 229 longevity of the immune response against SARS-CoV-2. 230

231

232 To further explore the immunogenic characteristics of the antibodies obtained from memory B cells in 3-dose vaccinees, 48 clonal antibodies, designated as XGv01 to 233 XGv50 (no expression for XGv37 and XGv48) were expressed and their antigen 234 binding abilities verified by ELISA (fig. S8). Biolayer interferometry affinities (BLI) 235 measurements demonstrated that all antibodies bound to WT SARS-CoV-2 at sub-236 nM levels (fig. S9 and table S1). The normalized geometric mean ELISA half-237 maximal concentration (EC₅₀) revealed that all antibodies (EC₅₀=4.5 ng/ml) obtained 238 from 3-dose vaccinees, in particular RBD-specific mAbs (EC₅₀=3.5 ng/ml), 239 240 possessed higher binding activities than RBD-mAbs from early convalescents (at 1.3 and 6.2 months after infection, EC₅₀=5.0 and 6.8 ng/ml, respectively) and mRNA 241 (EC₅₀=4.4 ng/ml) vaccinated individuals (2, 14-18), but were comparable to those 242 from late convalescent individuals (EC₅₀=2.6 ng/ml) assessed at 12 months after 243 infection (Fig. 2E). These results indicate the possibility of the loss of antibodies 244 with low binding affinities over time or an ongoing increase in affinity under the 245

repeated exposures of antigen. Among these antibodies tested, 26 bound to RBD, 16 246 247 targeted NTD, and 6 interacted with neither RBD nor NTD, but bound S1 (S1/non-RBD-NTD) (fig. S9 and table S1). Pseudovirus neutralization assay revealed that all 248 RBD-specific antibodies, 10 (~60%) of the 16 NTD-directed antibodies and 3 249 250 (~50%) of the 6 S1/non-RBD-NTD antibodies were neutralizing, presenting a relatively high ratio for NAbs (Fig. 2F, fig. S10 and table S2). Authentic SARS-CoV-251 2 neutralization assay results largely verified their neutralizing activities, albeit with 252 253 that higher concentrations were required for some NAbs (fig. S11). Compared to 254 RBD antibodies, many NTD NAbs exhibited very limited neutralizing activities. Notably, approximately 30% of RBD antibodies showed extra potent activities with 255 half-maximal inhibitory concentration values (IC₅₀) < 0.1 nM. In line with binding 256 affinity, the normalized geometric mean IC₅₀ of the RBD antibodies of 3-dose 257 vaccinees was 80 ng/ml, substantially lower than those from naturally infected 258 individuals (ranging from 1.3 to 6.2 months, IC₅₀=130-160 ng/ml) and mRNA 259 vaccinated individuals (IC₅₀=150 ng/ml), but similar to those from late convalescents 260 $(IC_{50}=78 \text{ ng/ml})$ (Fig. 2E) (2, 14-18). The overall increased neutralizing potency 261 might have resulted from the ongoing accumulation of clones expressing antibodies 262 263 with tight binding and potent neutralizing activities. Our experimental observations are consistent with a more recent study where antibodies generated from clonal B 264 cells after 12 months showed enhanced neutralizing activities (14, 15). 265

266

To examine the cross-reactivity against VOCs and other human coronaviruses, 267 binding responses of these antibodies to WT, B.1.1.7, P.1, B.1.351, B.1.617.2, SARS-268 CoV, HuCoV NL63, HuCoV 229E and HuCoV HKU1 were measured. All but 2 of 269 the 48 antibodies showed strong cross-binding to SARS-CoV-2 VOCs and about one-270 271 third of antibodies exhibited clear cross-reactivity to SARS-CoV, but none of these bound to HuCoV NL63, HuCoV 229E or HuCoV HKU1 (fig. S12). For ~ 20% and 272 25% of RBD- and NTD-targeting antibodies, respectively, binding affinities against 273 B.1.351/B.1.617.2 were over 10-fold reduced compared with WT (Fig. 2E). To 274 further determine the neutralization breadth, the neutralizing activity of these 275 276 antibodies was assayed against five VOCs and SARS-CoV. Out of 26 RBD NAbs,

24 possessed cross-neutralization activity against all five SARS-CoV-2 VOCs (Fig. 277 278 2F and fig. S13). Among these, six RBD antibodies could cross-neutralize SARS-CoV, of which 2 exhibited more potent neutralization activity against SARS-CoV 279 with IC₅₀ values of 41 and 73 ng/ml. However, most of the NTD and S1/non-RBD-280 NTD NAbs lost their abilities to inhibit viral infection (Fig. 2F and fig. S13), 281 indicative of higher variations for the NTD in VOCs. In comparison with NAbs from 282 early convalescents, antibodies isolated from 3-dose vaccinees showed overall 283 enhanced neutralizing potency and breadth to VOCs. 284

285

RBD is one of the main targets of neutralization in SARS-CoV-2 and other 286 coronaviruses. Due to its inherent conformational flexibility, RBD exists in either an 287 "open" (ACE2 receptor accessible) or "closed" (ACE2 receptor inaccessible) 288 configuration (19, 20), bearing antigenic sites with distinct "neutralizing sensitivity". 289 To dissect the nature of the epitopes of RBD targeted by NAbs, 171 SARS-CoV-2 290 RBD-targeting NAbs with available structures (2, 15, 21-82), including 8 cryo-EM 291 structures determined in this manuscript (fig. S14-S15 and table S3), were examined. 292 293 By using cluster analysis on epitope structures, the antibodies were primarily 294 classified into six sites (I, II, III, IV, V and VI) (Fig. 3A and fig. S16), that are related to the four or five classes assigned in recent studies (22, 31). Additionally, we 295 superimposed structures of RBDs from these complex structures and calculated the 296 clash areas between any 2 NAbs (Fig. 3B). Both strategies yielded identical results. 297 Combining the results of the characterization of binding and neutralization studies 298 reported previously with those determined here, the key structure-activity correlates 299 for the six classes of antibodies were analyzed (Fig. 3). Antibodies with sites I, II and 300 301 III, most frequently elicited by SARS-CoV-2 early infection, target the receptor-302 binding motif (RBM), and potently neutralize the virus by blocking the interactions between SARS-CoV-2 and ACE2 (Fig. 3C and D). Class I antibodies, mostly derived 303 from IGHV3-53/IGHV3-66 with short HCDR3s (generally <15 residues), recognize 304 only the "open" RBD, and make contact with K417 and N501, but not 305 L452/T478/E484 (Fig. 3C and D, and fig. S16-S17). Notably, mutations such as 306 K417N, L452R, T478K, E484K and N501Y, or combinations of these mutations, 307

identified in several VOCs like B.1.1.7, B.1.617.2, P.1 and B.1.351, have been 308 309 demonstrated to be key determinants for the viral escape of neutralization by many NAbs (fig. S18) (1, 81). Approximately ~75% and 60% of class I NAbs were 310 significantly impaired in binding and neutralizing activities against B.1.351 as well 311 as P.1, respectively, due to the combined mutations of K417N/T and N501Y (Fig. 3D 312 and E, and fig. S18). Contrarily, Class III antibodies that are encoded by IGHV1-2 313 and other variable heavy (VH)-genes and bound to RBD either in "open" or "closed" 314 conformation, extensively associate with E484, and partially with L452, but not 315 316 K417/T478/N501 (Fig. 3D and fig. S17C). Interestingly, IGHV3-53/IGHV3-66 RBD antibodies with long HCDR3s (>15 residues) switch their epitopes from the site I to 317 site III, indicating a clear antigenic drift during the process of somatic 318 hypermutations (fig. S17C). Disastrously, over 90% class III antibodies showed a 319 complete loss of activity against B.1.351 as well as P.1 largely owing to an E484K 320 mutation (Fig. 3E). Against B.1.617.2, the substantially decreased activity of ~half 321 of the class III antibodies is presumably mediated by L452R (Fig. 3E). Class II 322 antibodies use more diverse VH-genes and target the patch lying between sites I and 323 324 III (Fig. 3D and fig. S19). Surprisingly, antibodies binding to site II possess relatively 325 lower specificity in recognition of epitope clusters ranging from K417, L452, S477, E484 to N501 (fig. S16). Like site I, site II can only be accessed when the RBD is in 326 "open" conformation (Fig. 3A). As expected, the effects of mutations on the activity 327 of class II antibodies were severe, two-thirds of these antibodies had >10-fold fall in 328 neutralization activities against VOCs (Fig. 3E). Overall, the above analysis reveals 329 that the RBD mutations identified in several VOCs can significantly reduce and, in 330 some cases, even abolish the binding and neutralization of classes I to III antibodies, 331 332 albeit being the most potent neutralizing antibodies against WT SARS-CoV-2.

333

By contrast, antibodies of the other three classes recognize evolutionarily conserved regions distinct from the RBM and some of these are often cross-reactive with other sarbecoviruses (*65-67*, *79*). The binding of class IV antibodies, albeit attached to the apical shoulder of the RBM, is focused on a condensed patch that comprises residues 345-346, 440-441, 444-446, 448-450, which are not related to mutations observed in

VOCs (Fig. 3C and fig. S16). Related to the binding position, site IV epitopes, 339 accessible in both "open" and "closed" conformations, exist either as partially 340 overlapped with or outside ACE2 binding sites (Fig. 3A). Interestingly, class IV 341 antibodies can execute their neutralizations via multiple mechanisms, such as (i) 342 343 direct blockage of RBD-ACE2 associations, (ii) bridging adjacent "closed" RBDs to lock the S-trimer into a completely closed prefusion conformation, (iii) blockage of 344 viral membrane fusion by locking conformational changes of the S-trimer, or (iv) Fc-345 dependent effector mechanisms (31, 62, 67). Class IV antibodies, e.g. 1-57, 2-7, S309 346 347 and BD-812, hold the greatest potential for harboring ultra-potent neutralization activity and markedly high tolerance to most VOCs (63, 67). Not surprisingly, all class 348 IV antibodies, but CV07-270, exhibited excellent neutralizing breadth and potency to 349 VOCs (Fig. 3E). The probable reason underlying the exception could be that CV07-350 270 bears an unusually long HCDR3, directly contacting E484, distal to the site IV (46). 351 Site V locates beneath the RBM ridge, opposite to the site I, and adjacent to the site 352 III. None of the class V antibodies compete with ACE2 binding (Fig. 3D and fig. 353 S17). Due to ~40% targeting frequency to L452, B.1.617.2, but not other VOCs, 354 partially decreased the activities of some class V antibodies (Fig. 3E). Class VI 355 356 antibodies recognize a patch on one side of the RBD, distal from the RBM. Among these, some compete with ACE2 binding, while some do not, and this largely depends 357 on the orientation/pose of the antibodies bound. Both sites V and VI contain cryptic 358 epitopes that are only accessible when at least one RBD is in the open state (Fig. 3A 359 and C). In some cases, e.g. FC08 and CR3022, belonging to class V and VI, 360 respectively, epitopes are only accessible in the prefusion S-trimer under the 361 condition that all RBDs are open, suggesting that binding of these antibodies would 362 facilitate the destruction of the prefusion S-trimer (83, 84). In spite of less potency, 363 antibodies targeting sites V to VI are mostly tolerant to the VOCs. 364

365

Low levels of NAbs elicited by either natural infection or vaccination during *in vivo* viral propagation may impose strong selection pressure for viral escape, leading to an increase in the number of SARS-CoV-2 variants. To further understand the drivers of viral evolution, we constructed immunogenic and mutational heatmaps for RBD 370 using the 171 NAb complex structures to estimate in vivo NAb-targeting frequencies 371 on the RBD and viral mutation frequencies (calculated from the datasets in the GISAID), respectively (Fig. 3D and fig. S19). Briefly, for each antibody, we 372 identified epitope residues and calculated the frequency of each RBD residue being 373 374 recognized by antibody. Immunogenic heatmap revealed that the epitope residues of sites I to III showed predominantly higher NAb recognition frequencies (about 53.8, 375 55.0 and 49.2 antibodies per residue on average for site I, II and III, respectively) 376 compared with those of sites IV to VI (about 19.4, 9.1 and 14.3 antibodies per 377 378 residues on average for site IV, V and VI, respectively), suggesting that class I to III antibody epitopes are "hot" immunogenic sites (Fig. 3D and fig. S19). In line with 379 this, residues within sites I to III exhibited dramatically higher mutation frequencies, 380 as revealed in circulating variants that include mutations of K417, L452, S477, T478, 381 E484 and N501 residues (Fig. 3D and fig. S19). Surprisingly, none of the top 9 hottest 382 immunogenic residues had a high mutation frequency. In particular, residues, such 383 as F486, Y489, Q493, L455, F456, et.al (top 5, having 96, 96, 81, 73 and 70 384 antibodies per residue, respectively) with large side chains exhibited extremely low 385 mutation frequencies in circulating SARS-CoV-2 strains (Fig. 3D and fig. S20). It's 386 worthy to note that all these residues are extensively involved in the recognition of 387 ACE2. The buried surface area (BSA) of these residues upon binding to ACE2 388 confirmed that extensive interactions would be significantly reduced by amino acid 389 substitutions, thereby affecting ACE2-mediated viral entry. Thus, genetic, structural 390 and immunogenic analysis explains why mutations at these positions would not be 391 selected. 392

393

A few studies have reported that a subset of NTD-targeting antibodies can be as potent as best-in-class RBD specific antibodies. They work *via* inhibiting a step postattachment to cells like blocking fusion of the virus to the host cell membrane (*85-88*). We performed cluster analysis on 26 structures of the NTD-NAb complexes (including 2 structures solved in this manuscript) (fig. S21A) (*54*, *85-93*). A dominant site α , defined as the "supersite" in more recent studies (*85-88*), comprising of three flexible loops (N1, N3 and N5), is the largest glycan-free surface of NTD

facing away from the viral membrane (facing up). Antibodies targeting site α 401 402 generally exhibited the most potent neutralizing activity compared to other sites on the NTD (85, 90) (fig. S21B and C). The NTD supersite antibodies are primarily 403 derived from a subset of VH-genes with an over-representation of IGHV1-24. Sites 404 β and γ , as the left and right flank clusters, construct a shallow groove beneath the 405 supersite and locate at the back of the groove, eliciting less potent antibodies. By 406 contrast, δ antibodies, bound to a patch beneath the groove have their Fab constant 407 domains directed downward toward the virus membrane (facing down) (fig. S21B 408 409 and C). In line with binding orientation, many of the δ antibodies were shown to present infection enhancing activities in vitro (54, 90). Perhaps correlated with being 410 a "hot" immunogenic site that is amenable to potent neutralization, highly frequent 411 mutations, including a number of deletions within the NTD supersite were identified 412 in most VOCs under ongoing selective pressure, leading to significant reduction and 413 in some cases even complete loss of neutralization activity for these NTD supersite 414 NAbs (94). 415

416

417 More recent studies have reported that SARS-CoV-2 infection can produce a long-418 lasting memory compartment that continues to evolve over 12 months after infection with ongoing accumulation of somatic mutations, emergence of new clones and 419 increasing affinity of antibodies to antigens (14, 15). Consequently, an increase in 420 breadth and overall potency of antibodies produced by memory B cells over time has 421 been revealed (14), akin to the experimental observations elicited by a 3-dose 422 vaccination strategy using an inactivated vaccine described in this study. To 423 investigate whether changes in the frequency of distribution of the six types of RBD 424 425 antibodies is associated with evolution time, we collated and categorized human 426 SARS-CoV-2 NAbs from available literatures. For antibody clustering, we combined structural and square competition matrix analysis for 273 RBD NAbs in total (Fig. 427 4A and fig. S22). In the earliest documented studies (before Dec 2020), NAbs 428 belonging to classes I to III were predominantly identified in early COVID-19 429 convalescent and 2-dose vaccinated individuals (defined as early time point), 430 accounting for up to ~80% of total antibodies. By contrast, a low ratio of NAbs from 431

IV to VI was reported possibly due to their less potent activities at the early time 432 433 point (Fig. 4A). In recent literatures (after Dec 2020), NAbs with enhanced neutralizing potency and breadth from IV to VI have substantially been enriched in 434 the late convalescents or 3-dose vaccinees, almost equal in frequency to antibodies 435 from I to III and further becoming ascendant in individuals immunized with 3 doses 436 of inactivated vaccine (Fig. 4A). Differential frequency of distribution of antibody 437 types may provide an additional possible explanation for the observed enhanced 438 neutralizing breadth of plasma in late convalescent individuals and 3-dose vaccinees. 439 These results suggest that memory B cells display clonal turnover after about 6 440 months, subsequently resulting in changes in the composition of antibodies in B cell 441 repertoire and thereby partially contributing to enhanced activities of antibodies 442 secreted in the plasma over time. To explore the underlying mechanism, we measured 443 the binding affinities of 167 type-classified antibodies that are also further 444 categorized into early and late time point groups (table S1 and fig. S9). For the late 445 time group, there was a 10-20 fold increase in binding affinity for individual classes, 446 compared to those in the early time point group (Fig. 4B). In early time point group, 447 antibodies from IV to VI exhibited higher binding affinities to the RBD than those 448 449 from I to III, in particular, antibodies from V and VI despite limited numbers (Fig. 4B). Possibly higher affinities for these antibodies are required to accomplish 450 neutralization successfully. Thus, most antibodies from V and VI with low affinities 451 and activities might be screened out in the early time point. In the late point group, 452 sub-nM binding affinities for individual class antibodies with no distinct variations 453 were observed, reflecting ongoing affinity maturation over time. This might also 454 explain the observation that some antibodies, from I to III isolated in the late time 455 point possess potent cross-neutralization activities (Fig. 3E). Our antibody clustering 456 and V gene usage analysis suggests that individual class antibodies can be derived 457 from multiple V genes and the shared V gene antibodies belong to different classes. 458 To decipher the intrinsic trends in the relationship between binding affinity and 459 somatic hypermutation (SHM) rate, we determined the relative affinity (K_D) and 460 calculated the SHM rate of antibodies that are encoded by the same V gene and 461 belong to the same class. The measured K_D -SHM plots and K_D -SHM log-log plots of 462

class I antibodies (n=61), including 32 NAbs derived from IGHV3-53, show least 463 464 squares fitting of data to a power law with a strong correlation of -0.81 for IGHV3-53 antibodies (-0.55 for all class I antibodies) (Fig. 4C). The absolute value of its slope 465 corresponding to a free energy change per logarithm (base e) SHM of cal nmol⁻¹, 466 where free energy change is $4.98RT + 1.48RT \ln(SHM)$ (R = 2.0 cal K⁻¹ nmol⁻¹ 467 and T = 298 K). Antibodies with adequate numbers tested from II and III exhibited 468 similar trends by following a power law, among which IGHV3-66 antibodies in class 469 II yielded a compelling correlation of -0.94 despite 6 plots involved in the fitting 470 471 (Fig. 4C). These trends indicate that as the SHM increase, the binding energy 472 increases and K_D value decreases.

473

474 More recently, the B.1.617.2 variant has contributed to another surge in COVID-19 cases worldwide, accounting for $\sim 90\%$ of new cases in the UK and $\geq 40\%$ in the US, 475 despite the fact that increasing number of people have been vaccinated. Evaluation 476 of the effectiveness of several vaccines performed recently suggests that the efficacy 477 for VOCs correlates with full vaccination status and the time that has passed since 478 vaccination (95, 96). These may indicate that the effectiveness of the vaccines has 479 480 started to decline as months pass after vaccination due to fading immunity. Our results demonstrate that a third-dose booster of inactivated vaccine can elicit an 481 expeditious, robust and long-lasting recall humoral response which continues to 482 evolve with ongoing accumulation of somatic mutations, emergence of new clones 483 and increasing affinities of antibodies to antigens, conferring enhanced neutralizing 484 potency and breadth. Collectively, our findings rationalize the use of 3-dose 485 vaccination regimens. 486

487

488

Acknowledgments: We thank Dr. Xiaojun Huang, Dr. Boling Zhu, Dr. Lihong Chen, Dr. Xujing Li and Dr. Gang Ji for cryo-EM data collection, the Center for Biological Imaging (CBI) in Institute of Biophysics for EM work and thank Dr. Yuanyuan Chen, Zhenwei Yang for technical help with BLI experiments. We also thank Prof. David Ho and Prof. Barton Ford Haynes for generous gift of the sequences of two reference mAbs. Work was supported by the Strategic Priority Research Program

(XDB29010000, XDB37030000), CAS (YSBR-010), National Key Research and 495 Development Program (2020YFA0707500, 2018YFA0900801), Emergency Key 496 Program of Guangzhou Laboratory, Grant No. EKPG21-09 and Beijing Municipal 497 Science and Technology Project (Z201100005420017). Xiangxi Wang was supported 498 by Ten Thousand Talent Program and the NSFS Innovative Research Group (No. 499 81921005). Author contributions: X.W., Q.W., Y.W., X.S.X and Y.C. conceived, 500 designed and coordinated the experiments. Y.Z., A.Y., Y.W., Q.Z. and J-B.W. cloned 501 502 and produced antibodies. K.W., Z.J., K.F., J.M., Y.J. and L.Q. expressed and purified all recombinant antigen proteins used in this manuscript. J-J.W., Y.H., L.W., J.L., X.G., 503 Y-J.Z., H.Z. and B-S.L performed pseudovirus and authentic virus neutralization 504 experiments. K.W., L.W., P. L., WJ.F, N.W and L.Z performed structural study. Y.C., 505 Y.Z., W.W. and Y.G. prepared PBMCs and flow cytometry sorting. Y.C. and A.Y. 506 performed 10X sequencing library construction. Z.J. and K.F performed BLI assay. 507 Y.H. and Q.G recruited volunteers and coordinated the collection of blood samples. All 508 authors analyzed data; X.W wrote the manuscript with input from all authors. 509 Competing interests: All authors have no competing interests. Data and materials 510 availability: Cryo-EM density maps of the SARS-CoV-2 S trimer in complex with 511 XGv013 or XGv043, the SARS-CoV-2 S trimer in complex with XGv004, XGv030 512 513 and XGv016; the SARS-CoV-2 S trimer in complex with XGv026 and XGv046, and the SARS-CoV-2 S trimer in complex with XGv018, XGv038 and XGv42 have been 514 deposited at the Electron Microscopy Data Bank with accession codes EMD-UUUU, 515 EMD-WWWW, EMD-XXXX, EMD-YYYY and EMD-ZZZZ, respectively. 516 517

- 518
- 519
- 520
- 521
- 522
- 523
- 524
- **Figure legends** 525



Fig. 1 A 3rd-dose booster of an inactivated vaccine elicits an expeditious and
 long-lasting recall antibody response

Plasma neutralizing activity evaluated by authentic SARS-CoV-2 (A) and pseudo-529 530 typed SARS-CoV-2 neutralization assays (B) Left: half-maximal neutralizing titer (NT₅₀) values for plasma from COVID-19 convalescents, 2-dose, 3-dose CoronaVac 531 vaccine recipients (at week 4 after the last dose of vaccination) and negative controls 532 (pre-COVID-19 historical control) against live SARS-CoV-2 WT, B.1.351, P.1 and 533 B.1.617.2, and VSV-based SARS-CoV-2 pseudoviruses bearing WT or B.1.1.7 or P.1 534 S protein. Black bars and indicated values represent geometric mean NT₅₀ values. 535 Statistical significance was determined using the two-tailed Wilcoxon matched-pairs 536 test. Experiments were repeated in triplicate. Dotted lines indicate the limit of 537 538 detection. Right: fold decrease in neutralization for each variant relative to WT for

- each cohort of plasma samples (calculated from the left datasets) is shown.
- 540 (C) IgG endpoint antibody responses specific to the N, RBD and S of WT SARS-
- 541 CoV-2 were measured in plasma samples collected from cohorts as described earlier.
- 542 (D) Fold decrease in specific binding to the RBD, NTD and S for each variant over
- 543 WT for each cohort of plasma samples as described above.
- 544 (E) IgA, IgM and IgG endpoint antibody titers specific to the S of WT SARS-CoV-
- 2 or its variants in plasma samples collected from vaccinees before and 4 weeks after
 the 3rd-dose immunization.
- 547 (F) Neutralizing titers against live SARS-CoV-2 WT, P.1, B.1.351 and B.1.617.2 for
- plasma from vaccinees before and 4 weeks after the 3rd-dose immunization. Black
 bars and indicated values represent geometric mean NT₅₀ values.
- (G) Longitudinal neutralizing titers of plasma from 3-dose vaccinees at days 0, 7, 14, 28, 90 and 180 post the 3^{rd} -dose vaccination. The geometric mean NT₅₀ values are labeled.
- (H) Kinetics of the 3rd-dose booster elicited recall response as indicated during
 monitoring of NAb titers at different time points. The green and blue curves show
 the changes in kinetics of NAb titers for pre-3rd-dose and post-3rd-dose vaccination,
 respectively.
- 557
- 558
- 559
- 560
- 561
- 562
- 563

- 566
- 567



Fig. 2 Memory B cell antibodies elicited by a 3rd-dose booster of an inactivated vaccine

571 (A) Representative flow cytometry plots showing dual allophycocyanin (APC)-S572 and phycoerythrin (PE)-S-binding B cells for vaccinees and control donor.

(B) Pie charts represent the distribution of antibody sequences from the four 3-dose
vaccinees. The number in the inner circle is the number of sequences analyzed here.
Pie-slice size is proportional to the number of clonally related sequences. The black
outline indicates the frequency of clonally expanded sequences detected individually.
Colored slices reveal clones that share the same *IGHV* and *IGLV* genes.

578 (C) Graph shows relative clonality among seven individuals who received 2-dose or
579 3-dose of inactivated vaccines. Relative clonality for COVID-19 convalescents

assayed at 1.3, 6.2 and 12 months after infection, as well as 2-dose mRNA vaccine

recipients (2, 14, 18), previously described by Michel's group, was compared. Black

horizontal bars indicate mean values. Statistical significance was determined usingtwo-tailed t-test.

- (**D**) Number of somatic nucleotide mutations in the *IGHV* (left) and *IGLV* (right) in antibodies from vaccinees, including 2-dose or 3-dose of inactivated vaccines and 2dose of mRNA vaccines and COVID-19 convalescents assayed at 1.3, 6.2 and 12 months after infection (2, 14, 18).
- (E) Normalized ELISA binding (EC_{50}) by antibodies isolated from the 3-dose inactivated and 2-dose mRNA vaccinees (ref) as well as COVID-19 convalescents to SARS-CoV-2 S trimer (left) and normalized pseudovirus neutralization activity (IC_{50}) (right) against SARS-CoV-2 assayed at 1.3, 6.2 and 12 months after infection (ref). Among these, eight antibodies reported by Michel's group were expressed and assessed for both binding by ELISA and pseudovirus neutralization activity for normalized comparison here. Black horizontal bars indicate mean values.
- 595 **(F)** BLI binding affinities (upper panel) and pseudo-typed virus neutralization 596 (bottom panel) by antibodies isolated from the 3-dose vaccinees to circulating SARS-
- 597 CoV-2 variants. Color gradient for upper panel indicates K_D values ranging from 0
- 598 (green), through 2.5 (yellow) and 5 (red) to 25 nM (purple). Gray suggests no/very
- limited binding activity (>1000 nM). Color gradient for bottom panel indicates IC_{50}
- 600 $\,$ values ranging from 0 (green), through 20 (yellow) and 200 (red) to 2000 ng/ml $\,$
- 601 (purple). Gray suggests no/very limited neutralizing activity (>2000 ng/ml).

602

- 603
- 604

605

- 606
- 607
- 608
- 609



611 Fig. 3 Structural landscape and immunogenic features of RBD NAbs

612 (A) Structure-based antigenic clustering of SARS-CoV-2 RBD NAbs. A total of 171

613 RBD NAbs with available structures were classified into six clusters (I, II, III, IV, V

and VI). NAbs that can block ACE2 binding or not are outlined by light pink and

615 light yellow, respectively. NAbs that can attach to the closed RBD or not are outlined

- 616 by gray blue and gray green, respectively.
- **(B)** Superimposition matrix of 171 RBD NAb structures' output from clashed areas
- $(Å^2)$ between variable regions of any two Fab fragments showing the clustering into

619 six antibody classes.

620 (C) Surface representative model of six types of NAbs bound to the RBD. Fab 621 fragments of six representative antibodies are shown in different colors and the RBD 622 is colored in gray. Insets illustrate the antigenic patches targeted by six representative 623 antibodies. Dashed dots indicate the overlaps between two adjacent antigenic 624 patches.

(D) Structural landscapes of the six classes of RBD NAbs (upper panel). Antigenic 625 patches (with targeting frequency >30%) recognized by six classes of NAbs are 626 627 outlined in the assigned color scheme (same to Fig. 3C), among which residues with "hot targeting frequency" (generally over 65%, but over 85% in class I) are shown 628 in bright colors corresponding to the patches they belong to. Residues involved in 629 two (such as Y489, L452) or three (such as F486) neighboring antigenic patches are 630 presented in a mixed color. Representative "hot" antigenic residues are labeled. 631 Middle: hot map for antigenic residues on the RBD. Per residue frequency 632 recognized by the 171 NAbs were calculated and shown. The top 9 of the hottest 633 antigenic residues and key residues with substitutions in several VOCs are marked 634 and labeled. Bottom: hot map for circulating variants with mutations on the RBD. 635 636 Mutation frequency for each residue was calculated based on the datasets from GISAID. 637

(E) Immunogenic characteristics of six classes of RBD-targeting NAbs. Hot maps 638 show relative fold changes in K_D values (up) and IC₅₀ values (down) against several 639 VOCs for the six classes of NAbs, including previously reported (97-108) and newly 640 isolated antibodies described in this manuscript. Color gradients for upper and 641 bottom panels indicate relative fold changes and are shown at right side. "-": no 642 related datasets in the original studies and related references are listed. Ref "A" 643 644 indicates that the datasets were produced in this manuscript. Other letters in Ref 645 correspond to different reference numbers shown as below. B - 91 and this manuscipt, C - 99 and this manuscript, D - 97, E - 30, 81, 103 and 104, F - 99, G - 90646 98, H - 100 and 108, J - 101, K - 94 and 102, L - 105 and 106, M - 94, N - 105, O 647 -107, P-82, Q-66, respectively. 648



650 Fig. 4 Antibody evolution and affinity maturation

(A) Uniform manifold approximation and projection (UMAP) plot displaying the antibodies defined as the early time point group (left) and late time point group (right). The antibodies are colored based on their cluster assignments by the hierarchical clustering algorithm. Antibodies from I to III and IV to VI are highlighted in cyan and gray blue background, respectively. Pie charts represent the frequency distribution of antibodies belonging to I to III and IV to VI. Antibodies isolated from 3-dose vaccinees are outlined by black lines.

658 **(B)** Dissociation constants (K_D) of the antibodies from I to VI. Individual class 659 antibodies are represented in colors corresponding to the classes they belong to. The 660 color scheme is same as Fig. 4A. BLI traces are shown in fig. S9.

(C) The measured K_D -SHM plots (left) and K_D -SHM log-log plots (right) of 661 antibodies from I and II are shown. IGHV3-53 and IGHV3-66 antibodies belonging 662 to class I and II are colored in yellow and green, respectively. The straight curves 663 and lines are the least squares fits of the data to the power law with the values of the 664 slope for IGHV3-53 and IGHV3-66 antibodies. The black curves and lines indicate 665 the fitting of antibodies from I or II; the yellow and green ones suggest the fitting of 666 IGHV3-53 and IGHV3-66 antibodies, respectively. The cyan lines are the 90% 667 predicted interval. 668

- 669
- 670

671 **References and Notes:**

- N. G. Davies, S. Abbott *et al.*, Estimated transmissibility and impact of SARS-CoV-2 lineage
 B.1.1.7 in England. *Science* **372**, (2021); published online EpubApr 9
 (10.1126/science.abg3055).
- 6752.Z. Wang, F. Schmidt *et al.*, mRNA vaccine-elicited antibodies to SARS-CoV-2 and676circulating variants. *nature*, 616–622 (2021)10.1038/s41586-021-03324-6).
- A. Muik, A. K. Wallisch *et al.*, Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus
 by BNT162b2 vaccine-elicited human sera. *Science* **371**, 1152-1153 (2021); published
 online EpubMar 12 (10.1126/science.abg6105).
- W. F. Garcia-Beltran, E. C. Lam *et al.*, Multiple SARS-CoV-2 variants escape neutralization
 by vaccine-induced humoral immunity. *Cell* **184**, 2372-2383 e2379 (2021); published
 online EpubApr 29 (10.1016/j.cell.2021.03.013).
- 6835.E. Hacisuleyman, C. Hale *et al.*, Vaccine Breakthrough Infections with SARS-CoV-2684Variants. N Engl J Med 384, 2212-2218 (2021); published online EpubJun 10685(10.1056/NEJMoa2105000).
- 6866.E. C. Sabino, L. F. Buss *et al.*, Resurgence of COVID-19 in Manaus, Brazil, despite high687seroprevalence. Lancet **397**, 452-455 (2021); published online EpubFeb 6688(10.1016/S0140-6736(21)00183-5).
- W. N. Chia, F. Zhu *et al.*, Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study. *The Lancet. Microbe* 2, e240-e249 (2021);
 published online EpubJun (10.1016/S2666-5247(21)00025-2).
- A. T. Widge, N. G. Rouphael *et al.*, Durability of Responses after SARS-CoV-2 mRNA-1273
 Vaccination. *N Engl J Med* 384, 80-82 (2021); published online EpubJan 7
 (10.1056/NEJMc2032195).
- 9. Y. Zhang, G. Zeng *et al.*, Safety, tolerability, and immunogenicity of an inactivated SARSCoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebocontrolled, phase 1/2 clinical trial. *Lancet Infect Dis* 21, 181-192 (2021); published online
 EpubFeb (10.1016/S1473-3099(20)30843-4).
- 69910.Q. Gao, L. Bao *et al.*, Development of an inactivated vaccine candidate for SARS-CoV-2.700Science 369, 77-81 (2020); published online EpubJul 3 (10.1126/science.abc1932).
- 11. D. S. Khoury, A. K. Wheatley *et al.*, Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models. *Nature reviews. Immunology* 20, 727-738 (2020); published online EpubDec (10.1038/s41577-020-00471-1).
- 12. L. Riepler, A. Rossler *et al.*, Comparison of Four SARS-CoV-2 Neutralization Assays.
 705 Vaccines 9, (2020); published online EpubDec 28 (10.3390/vaccines9010013).
- 70613.Q. W. Hongxing Pan, G. Zeng, Immunogenicity and safety of a third dose, and immune707persistence of CoronaVac vaccine in healthy adults aged 18-59 years: interim results from708a double-blind, randomized, placebo-controlled phase 2 clinical trial. *medRxiv*,709(2021)https://doi.org/10.1101/2021.07.23.21261026).
- 710 14. Z. Wang, F. Muecksch *et al.*, Naturally enhanced neutralizing breadth against SARS-CoV711 2 one year after infection. *Nature* 595, 426-431 (2021); published online EpubJul
 712 (10.1038/s41586-021-03696-9).
- 71315.F. Muecksch, Y. Weisblum *et al.*, Development of potency, breadth and resilience to viral714escape mutations in SARS-CoV-2 neutralizing antibodies. *bioRxiv*, (2021); published715online EpubMar 8 (10.1101/2021.03.07.434227).
- 716
 16.
 C. Gaebler, Z. Wang *et al.*, Evolution of antibody immunity to SARS-CoV-2. *Nature* **591**,

 717
 639-644 (2021); published online EpubMar (10.1038/s41586-021-03207-w).
- Y. Zhou, Z. Liu *et al.*, Enhancement versus neutralization by SARS-CoV-2 antibodies from
 a convalescent donor associates with distinct epitopes on the RBD. *Cell Rep* 34, 108699
 (2021); published online EpubFeb 2 (10.1016/j.celrep.2021.108699).
- 72118.D. F. Robbiani, C. Gaebler *et al.*, Convergent antibody responses to SARS-CoV-2 in722convalescent individuals. *Nature* 584, 437-442 (2020); published online EpubAug

723 (10.1038/s41586-020-2456-9).

- 72419.A. C. Walls, Y. J. Park *et al.*, Structure, Function, and Antigenicity of the SARS-CoV-2 Spike725Glycoprotein. *Cell* **181**, 281-292 e286 (2020); published online EpubApr 16726(10.1016/j.cell.2020.02.058).
- 72720.D. Wrapp, N. Wang *et al.*, Cryo-EM structure of the 2019-nCoV spike in the prefusion728conformation. Science **367**, 1260-1263 (2020); published online EpubMar 13729(10.1126/science.abb2507).
- R. Yan, R. Wang *et al.*, Structural basis for bivalent binding and inhibition of SARS-CoV-2
 infection by human potent neutralizing antibodies. *Cell Res* **31**, 517-525 (2021); published
 online EpubMay (10.1038/s41422-021-00487-9).
- W. Dejnirattisai, D. Zhou *et al.*, The antigenic anatomy of SARS-CoV-2 receptor binding
 domain. *Cell* **184**, 2183-2200 e2122 (2021); published online EpubApr 15
 (10.1016/j.cell.2021.02.032).
- 736 23. M. Yuan, H. Liu *et al.*, Structural basis of a shared antibody response to SARS-CoV-2.
 737 *Science* 369, 1119-1123 (2020); published online EpubAug 28 (10.1126/science.abd2321).
- 73824.F. Bertoglio, V. Fuhner *et al.*, A SARS-CoV-2 neutralizing antibody selected from COVID-73919 patients binds to the ACE2-RBD interface and is tolerant to most known RBD740mutations. *Cell Rep* **36**, 109433 (2021); published online EpubJul 27741(10.1016/j.celrep.2021.109433).
- 742 25. S. A. Clark, L. E. Clark *et al.*, Molecular basis for a germline-biased neutralizing antibody
 743 response to SARS-CoV-2. *bioRxiv*, (2020); published online EpubNov 13
 744 (10.1101/2020.11.13.381533).
- 745 26. B. B. Banach, G. Cerutti *et al.*, Paired heavy and light chain signatures contribute to potent
 746 SARS-CoV-2 neutralization in public antibody responses. *bioRxiv*, (2021); published
 747 online EpubJan 3 (10.1101/2020.12.31.424987).
- 748 27. B. E. Jones, P. L. Brown-Augsburger *et al.*, The neutralizing antibody, LY-CoV555, protects
 749 against SARS-CoV-2 infection in nonhuman primates. *Sci Transl Med* 13, (2021);
 750 published online EpubMay 12 (10.1126/scitranslmed.abf1906).
- Y. Guo, L. Huang *et al.*, A SARS-CoV-2 neutralizing antibody with extensive Spike binding
 coverage and modified for optimal therapeutic outcomes. *Nat Commun* 12, 2623 (2021);
 published online EpubMay 11 (10.1038/s41467-021-22926-2).
- S. Du, Y. L. Cao *et al.*, Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in
 Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy. *Cell* 183,
 1013-+ (2020); published online EpubNov 12 (10.1016/j.cell.2020.09.035).
- W. Dejnirattisai, D. M. Zhou *et al.*, Antibody evasion by the P.1 strain of SARS-CoV-2. *Cell* **184**, 2939-+ (2021); published online EpubMay 27 (10.1016/j.cell.2021.03.055).
- 759 31. C. O. Barnes, C. A. Jette *et al.*, SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. *Nature* 588, 682-+ (2020); published online EpubDec 24 (10.1038/s41586-020-2852-1).
- 762 32. N. C. Wu, M. Yuan *et al.*, An Alternative Binding Mode of IGHV3-53 Antibodies to the
 763 SARS-CoV-2 Receptor Binding Domain. *Cell Reports* 33, (2020); published online
 764 EpubOct 20 (10.1016/J.Celrep.2020.108274).
- 765 33. H. J. Liu, N. C. Wu *et al.*, Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally
 766 Conserved Site Is Mediated by Avidity. *Immunity* 53, 1272-+ (2020); published online
 767 EpubDec 15 (10.1016/j.immuni.2020.10.023).
- N. K. Hurlburt, E. Seydoux *et al.*, Structural basis for potent neutralization of SARS-CoV-2
 and role of antibody affinity maturation. *Nature Communications* **11**, (2020); published
 online EpubOct 27 (10.1038/S41467-020-19231-9).
- Y. Wu, F. R. Wang *et al.*, A noncompeting pair of human neutralizing antibodies block
 COVID-19 virus binding to its receptor ACE2. *Science* 368, 1274-+ (2020); published
 online EpubJun 12 (10.1126/science.abc2241).

- 77436.R. Shi, C. Shan *et al.*, A human neutralizing antibody targets the receptor-binding site of775SARS-CoV-2. Nature 584, 120-+ (2020); published online EpubAug 6 (10.1038/s41586-776020-2381-y).
- J. W. Ge, R. K. Wang *et al.*, Antibody neutralization of SARS-CoV-2 through ACE2 receptor
 minicry. *Nature Communications* **12**, (2021); published online EpubJan 11
 (10.1038/s41467-020-20501-9).
- 780 38. C. O. Barnes, A. P. West *et al.*, Structures of Human Antibodies Bound to SARS-CoV-2
 781 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. *Cell* 182, 828-+
 782 (2020); published online EpubAug 20 (10.1016/j.cell.2020.06.025).
- H. P. Yao, Y. Sun *et al.*, Rational development of a human antibody cocktail that deploys
 multiple functions to confer Pan-SARS-CoVs protection. *Cell Research* **31**, 25-36 (2021);
 published online EpubJan (10.1038/s41422-020-00444-y).
- 78640.N. Wang, Y. Sun *et al.*, Structure-based development of human antibody cocktails against787SARS-CoV-2. *Cell Research* **31**, 101-103 (2021); published online EpubJan788(10.1038/s41422-020-00446-w).
- 78941.S. Miersch, Z. Li, Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced790Potency and Resistance to Escape Mutations. BioRxiv,791(2021)https://doi.org/10.1101/2020.10.31.362848).
- 42. C. J. Bracken, S. A. Lim *et al.*, Bi-paratopic and multivalent VH domains block ACE2 binding
 and neutralize SARS-CoV-2. *Nature chemical biology* **17**, 113-121 (2021); published
 online EpubJan (10.1038/s41589-020-00679-1).
- C. Zhang, Y. F. Wang *et al.*, Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections. *Nature Communications* 12, (2021); published online Epublan 11 (10.1038/s41467-020-20465-w).
- 44. L. Piccoli, Y. J. Park *et al.*, Mapping Neutralizing and Immunodominant Sites on the SARSCoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. *Cell* 183, 1024-+ (2020); published online EpubNov 12 (10.1016/j.cell.2020.09.037).
- 45. J. Hansen, A. Baum *et al.*, Studies in humanized mice and convalescent humans yield a
 802 SARS-CoV-2 antibody cocktail. *Science* 369, 1010-1014 (2020); published online
 803 EpubAug 21 (10.1126/science.abd0827).
- 46. J. Kreye, S. M. Reincke *et al.*, A Therapeutic Non-self-reactive SARS-CoV-2 Antibody
 Protects from Lung Pathology in a COVID-19 Hamster Model. *Cell* 183, 1058-+ (2020);
 published online EpubNov 12 (10.1016/j.cell.2020.09.049).
- R. Rouet, O. Mazigi *et al.*, Potent SARS-CoV-2 binding and neutralization through
 maturation of iconic SARS-CoV-1 antibodies. *Mabs-Austin* 13, (2021); published online
 Epublan 1 (10.1080/19420862.2021.1922134).
- 48. M. A. Tortorici, M. Beltramello *et al.*, Ultrapotent human antibodies protect against SARS811 CoV-2 challenge via multiple mechanisms. *Science* **370**, 950-+ (2020); published online
 812 EpubNov 20 (10.1126/science.abe3354).
- 49. E. Rujas, I. Kucharska *et al.*, Multivalency transforms SARS-CoV-2 antibodies into ultrapotent neutralizers. *Nature Communications* 12, (2021); published online EpubJun 16 (10.1038/S41467-021-23825-2).
- 81650.J. Ahmad, J. Jiang *et al.*, Synthetic nanobody-SARS-CoV-2 receptor-binding domain817structures identify distinct epitopes. *bioRxiv*, (2021); published online EpubJan 27818(10.1101/2021.01.27.428466).
- 819 51. M. Schoof, B. Faust *et al.*, An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by
 820 stabilizing inactive Spike. *Science* **370**, 1473-1479 (2020); published online EpubDec 18
 821 (10.1126/science.abe3255).
- 82252.M. Rapp, Y. C. Guo *et al.*, Modular basis for potent SARS-CoV-2 neutralization by a823prevalent VH1-2-derived antibody class. *Cell Reports* **35**, (2021); published online824EpubApr 6 (10.1016/J.Celrep.2021.108950).

826 domain of SARS-CoV-2 spike protein. Nature Communications 12, (2021); published 827 online EpubJan 12 (10.1038/s41467-020-20602-5). 828 54. D. Li, R. J. Edwards et al., In vitro and in vivo functions of SARS-CoV-2 infection-enhancing 829 published online and neutralizing antibodies. Cell, (2021); EpubJun 18 830 (10.1016/j.cell.2021.06.021). 831 55. L. Hanke, L. V. Perez et al., An alpaca nanobody neutralizes SARS-CoV-2 by blocking 832 receptor interaction. Nature Communications 11, (2020); published online EpubSep 4 833 (10.1038/S41467-020-18174-5). 834 56. J. D. Huo, A. Le Bas et al., Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block 835 interaction with ACE2 (vol 27, pg 846, 2020). Nature Structural & Molecular Biology 28, 836 326-326 (2021); published online EpubMar (10.1038/s41594-021-00566-w). 837 57. B. Ju, Q. Zhang et al., Human neutralizing antibodies elicited by SARS-CoV-2 infection. 838 Nature 584, 115-+ (2020); published online EpubAug 6 (10.1038/s41586-020-2380-z). 839 58. Y. L. Cao, B. Su et al., Potent Neutralizing Antibodies against SARS-CoV-2 Identified by 840 High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells. Cell 182, 73-841 + (2020); published online EpubJul 9 (10.1016/j.cell.2020.05.025). 842 59. L. H. Liu, P. F. Wang et al., Potent neutralizing antibodies against multiple epitopes on 843 SARS-CoV-2 spike. Nature 584, 450-+ (2020); published online EpubAug 20 844 (10.1038/s41586-020-2571-7). 845 P. A. Koenig, H. Das et al., Structure-guided multivalent nanobodies block SARS-CoV-2 60. 846 infection and suppress mutational escape. Science 371, 691-+ (2021); published online 847 EpubFeb 12 (10.1126/science.abe6230). 848 61. Y. F. Xiang, S. Nambulli et al., Versatile and multivalent nanobodies efficiently neutralize 849 SARS-CoV-2. Science 370, 1479-1484 (2020); published online EpubDec 18 850 (10.1126/science.abe4747). 851 62. L. Zhu, Y. Q. Deng et al., Double lock of a potent human therapeutic monoclonal antibody 852 against SARS-CoV-2. National Science Review 8, (2021); published online EpubMar 853 (10.1093/nsr/nwaa297). 854 63. G. Cerutti, M. Rapp et al., Structural basis for accommodation of emerging B.1.351 and 855 B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies. Structure 29, 655-+ 856 (2021); published online EpubJul 1 (10.1016/j.str.2021.05.014). 857 64. T. F. Custodio, H. Das et al., Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2. Nature Communications 11, (2020); 858 859 published online EpubNov 4 (10.1038/S41467-020-19204-Y). 860 65. J. F. Scheid, C. O. Barnes et al., B cell genomics behind cross-neutralization of SARS-CoV-861 2 variants and SARS-CoV. Cell 184, 3205-+ (2021); published online EpubJun 10 862 (10.1016/j.cell.2021.04.032). 863 66. H. J. Liu, M. Yuan et al., A combination of cross-neutralizing antibodies synergizes to 864 prevent SARS-CoV-2 and SARS-CoV pseudovirus infection. Cell Host & Microbe 29, 806-865 + (2021); published online EpubMay 12 (10.1016/j.chom.2021.04.005). 866 67. D. Pinto, Y. J. Park et al., Cross-neutralization of SARS-CoV-2 by a human monoclonal 867 SARS-CoV antibody. Nature 583, 290-295 (2020); published online EpubJul 868 (10.1038/s41586-020-2349-y). 869 68. T. N. Starr, N. Czudnochowski et al., Antibodies to the SARS-CoV-2 receptor-binding 870 domain that maximize breadth and resistance to viral escape. *bioRxiv*, (2021). 871 69. D. M. Zhou, H. M. E. Duyvesteyn et al., Structural basis for the neutralization of SARS-872 CoV-2 by an antibody from a convalescent patient. Nature Structural & Molecular Biology 873 27, 950-+ (2020); published online EpubOct (10.1038/s41594-020-0480-y). 874 70. M. Yuan, N. C. Wu et al., A highly conserved cryptic epitope in the receptor binding 875 domains of SARS-CoV-2 and SARS-CoV. Science 368, 630-+ (2020); published online

C. Kim, D. K. Ryu et al., A therapeutic neutralizing antibody targeting receptor binding

825

53.

 877 71. Z. Lv, Y. Q. Deng <i>et al.</i>, Structural basis for neutralization of S 878 by a potent therapeutic antibody. <i>Science</i> 369, 1505-+ (2020) 879 18 (10.1126/science.abc5881). 880 72. Y. L. Cao, A. Yisimayi <i>et al.</i>, Humoral immune response to circu 981 elisited by inactivated and PPD subwrit vacaines. <i>Cell</i> Pre- 	
 by a potent therapeutic antibody. <i>Science</i> 369, 1505-+ (2020) 18 (10.1126/science.abc5881). 72. Y. L. Cao, A. Yisimayi <i>et al.</i>, Humoral immune response to circu aligited by inactivated and PPD subwrit variance. <i>Cell</i> Pro- 	ARS-CoV-2 and SARS-CoV
 879 18 (10.1126/science.abc5881). 880 72. Y. L. Cao, A. Yisimayi <i>et al.</i>, Humoral immune response to circu elicited by insetijuted and PPD subjust precises. <i>Cell</i>, Percentage 2011.); published online EpubSep
880 72. Y. L. Cao, A. Yisimayi <i>et al.</i> , Humoral immune response to circu	
901 aligited by inactivated and DDD subusit vacance Coll De-	llating SARS-CoV-2 variants
OOL EIICILEU DY INACLIVALEU AND KOD-SUDUNIT VACCINES. <i>Cell Res</i>	search 31 , 732-741 (2021);
882 published online EpubJul (10.1038/s41422-021-00514-9).	
883 73. Y. Sun, L. Wang <i>et al.</i> , Structure-based development of three-	and four-antibody cocktails
884 against SARS-CoV-2 via multiple mechanisms. <i>Cell Rese</i>	earch 31 , 597-600 (2021);
885 published online EpubMay (10.1038/s41422-021-00497-7).	
886 74. X. Zhu, D. Mannar <i>et al.</i> , Crvo-electron microscopy structures	of the N501Y SARS-CoV-2
887 spike protein in complex with ACE2 and 2 potent neutralizin	na antibodies. <i>PLoS Biol</i> 19,
888 e3001237 (2021): published online EpubApr (10.1371/iournal	.pbio.3001237).
889 75. D. Asarnow, B. Wang <i>et al.</i> , Structural insight into SARS-Co	V-2 neutralizing antibodies
890 and modulation of syncytia. <i>Cell</i> 184 . 3192-+ (2021): put	blished online Epublun 10
891 (10 1016/i cell 2021 04 033)	
892 76 X 1 Zhou E G Ma <i>et al</i> Diverse immunoglobulin gene usa	ge and convergent epitope
893 targeting in neutralizing antibody responses to SARS-CoV-	2 <i>Cell Reports</i> 35 (2021) [.]
894 published online EpubMay 11 (10 1016/i celrep 2021 109109)	
895 77 M E Jennewein A 1 MacCamy <i>et al.</i> Isolation and characteri	ization of cross-neutralizing
896 coronavirus antibodies from COVID-19+ subjects <i>Cell Rep</i> 3 :	6 109353 (2021): published
897 online Epublul 13 (10 1016/i celrep 2021 109353)	e , 100000 (2021), publicitor
898 78 T. N. Starr, N. Czudnochowski <i>et al.</i> SARS-CoV-2 RBD antibo	dies that maximize breadth
899 and resistance to escape. <i>Nature</i> 1-9 (2021)	
900 79 1 Fedry D L Hurdiss <i>et al.</i> Structural insights into the cross-	neutralization of SARS-CoV
901 and SARS-CoV-2 by the human monoclonal antibody 47	D11 Science Advances 7
902 (2021): published online Epublun (10 1126/sciady abf5632)	
903 80. K. Westendorf, S. Zentelis <i>et al.</i> , LY-CoV1404 potently neutra	alizes SARS-CoV-2 variants.
904 <i>bioRxiv.</i> (2021): published online EpubMay 4 (10.1101/2021.(04.30.442182).
905 81. C. Liu, H. M. Ginn <i>et al.</i> , Reduced neutralization of SARS-Co'	V-2 B.1.617 by vaccine and
906 convalescent serum. <i>Cell.</i> (2021): published	online EpubJun 17
907 (10.1016/i.cell.2021.06.020).	
908 82. L. Wang, T. Zhou <i>et al.</i> , Ultrapotent antibodies against diver	rse and highly transmissible
909 SARS-CoV-2 variants. <i>Science</i> . (2021); publishe	ed online EpubJul 1
910 (10.1126/science.abh1766).	, i
911 83. L. Zhang, L. Cao <i>et al.</i> . A proof of concept for neutralizing antik	odv-quided vaccine design
912 against SARS-CoV-2. <i>National Science Review</i> . (2020)10.109	3/nsr/nwab053).
913 84. J. Huo, Y. Zhao <i>et al.</i> , Neutralization of SARS-CoV-2 by Destru	ction of the Prefusion Spike.
914 <i>Cell Host Microbe</i> 28 445-454 e446 (2020): public	shed online EpubSep 9
915 (10.1016/i.chom 2020.06.010)	
	ic mapping reveals a site of
916 85. M. McCallum, A. De Marco <i>et al.</i> , N-terminal domain antigen	
916 85. M. McCallum, A. De Marco <i>et al.</i> , N-terminal domain antigen 917 vulnerability for SARS-CoV-2. <i>Cell</i> 184 , 2332-2347 e2316	6 (2021): published online
916 85. M. McCallum, A. De Marco <i>et al.</i> , N-terminal domain antigen 917 vulnerability for SARS-CoV-2. Cell 184, 2332-2347 e2316 918 EpubApr 29 (10.1016/i.cell.2021.03.028).	6 (2021); published online
 916 85. M. McCallum, A. De Marco <i>et al.</i>, N-terminal domain antigen 917 vulnerability for SARS-CoV-2. <i>Cell</i> 184, 2332-2347 e2316 918 EpubApr 29 (10.1016/j.cell.2021.03.028). 919 86. G. Cerutti, Y. Guo <i>et al.</i>, Potent SARS-CoV-2 neutralizing antib 	6 (2021); published online
 916 916 85. M. McCallum, A. De Marco <i>et al.</i>, N-terminal domain antigen vulnerability for SARS-CoV-2. <i>Cell</i> 184, 2332-2347 e2316 918 919 86. G. Cerutti, Y. Guo <i>et al.</i>, Potent SARS-CoV-2 neutralizing antib 920 920 	6 (2021); published online podies directed against spike be 29 , 819-833 e817 (2021);
91685.M. McCallum, A. De Marco <i>et al.</i> , N-terminal domain antigen917vulnerability for SARS-CoV-2. <i>Cell</i> 184 , 2332-2347 e2316918EpubApr 29 (10.1016/j.cell.2021.03.028).91986.920N-terminal domain target a single supersite. <i>Cell Host Microb</i> 921published online EpubMay 12 (10.1016/j.chom.2021.03.005).	6 (2021); published online bodies directed against spike be 29 , 819-833 e817 (2021);
 916 916 85. M. McCallum, A. De Marco <i>et al.</i>, N-terminal domain antigen vulnerability for SARS-CoV-2. <i>Cell</i> 184, 2332-2347 e2316 918 919 86. G. Cerutti, Y. Guo <i>et al.</i>, Potent SARS-CoV-2 neutralizing antib 920 921 921 922 87. X. Y. Chi, R. H. Yan <i>et al.</i> A neutralizing human antibody bind 	6 (2021); published online podies directed against spike <i>be</i> 29 , 819-833 e817 (2021); Is to the N-terminal domain
 916 916 85. M. McCallum, A. De Marco <i>et al.</i>, N-terminal domain antigen vulnerability for SARS-CoV-2. <i>Cell</i> 184, 2332-2347 e2316 918 919 86. G. Cerutti, Y. Guo <i>et al.</i>, Potent SARS-CoV-2 neutralizing antib 920 921 921 921 922 87. X. Y. Chi, R. H. Yan <i>et al.</i>, A neutralizing human antibody bind 923 924 925 	6 (2021); published online podies directed against spike be 29 , 819-833 e817 (2021); Is to the N-terminal domain + (2020); published online
91685.M. McCallum, A. De Marco <i>et al.</i> , N-terminal domain antigen917vulnerability for SARS-CoV-2. <i>Cell</i> 184 , 2332-2347 e2316918EpubApr 29 (10.1016/j.cell.2021.03.028).91986.G. Cerutti, Y. Guo <i>et al.</i> , Potent SARS-CoV-2 neutralizing antib920N-terminal domain target a single supersite. <i>Cell Host Microb</i> 921published online EpubMay 12 (10.1016/j.chom.2021.03.005).92287.X. Y. Chi, R. H. Yan <i>et al.</i> , A neutralizing human antibody bind923of the Spike protein of SARS-CoV-2. <i>Science</i> 369 , 650924EpubAug 7 (10.1126/science.abc6952).	6 (2021); published online bodies directed against spike be 29 , 819-833 e817 (2021); Is to the N-terminal domain + (2020); published online
 916 917 918 918 919 920 94. G. Cerutti, Y. Guo <i>et al.</i>, Potent SARS-CoV-2. <i>Cell</i> 184, 2332-2347 e2316 919 920 93. G. Cerutti, Y. Guo <i>et al.</i>, Potent SARS-CoV-2 neutralizing antib 920 921 921 922 937. X. Y. Chi, R. H. Yan <i>et al.</i>, A neutralizing human antibody bind 923 924 925 88. W. N. Voss, Y. X. J. Hou <i>et al.</i>, Prevalent, protective, and cor 	6 (2021); published online podies directed against spike be 29 , 819-833 e817 (2021); is to the N-terminal domain + (2020); published online nvergent IgG recognition of

927 EpubJun 4 (10.1126/science.abg5268).

- 92889.A. Rosa, V. E. Pye *et al.*, SARS-CoV-2 can recruit a heme metabolite to evade antibody929immunity. Science Advances 7, (2021); published online EpubMay930(10.1126/sciadv.abg7607).
- 93. Y. F. Liu, W. T. Soh *et al.*, An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies. *Cell* **184**, 3452-+ (2021); published online EpubJun 24 (10.1016/j.cell.2021.05.032).
- 934 91. P. J. M. Brouwer, T. G. Caniels *et al.*, Potent neutralizing antibodies from COVID-19
 935 patients define multiple targets of vulnerability. *Science* 369, 643-+ (2020); published
 936 online EpubAug 7 (10.1126/science.abc5902).
- 937 92. T. Noy-Porat, A. Mechaly *et al.*, Therapeutic antibodies, targeting the SARS-CoV-2 spike
 938 N-terminal domain, protect lethally infected K18-hACE2 mice. *Iscience* 24, (2021);
 939 published online EpubMay 21 (10.1016/j.isci.2021.102479).
- 940 93. J. Goike, C. L. Hsieh et al., Synthetic repertoires derived from convalescent COVID-19 941 patients enable discovery of SARS-CoV-2 neutralizing antibodies and a novel quaternary 942 bindina modality. bioRxiv, (2021); published online EpubApr 9 943 (10.1101/2021.04.07.438849).
- 94. P. Wang, M. S. Nair *et al.*, Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
 945 *Nature* 593, 130-135 (2021); published online EpubMay (10.1038/s41586-021-03398-2).
- 946 95. J. Lopez Bernal, N. Andrews *et al.*, Effectiveness of Covid-19 Vaccines against the B.1.617.2
 947 (Delta) Variant. *N Engl J Med*, (2021); published online EpubJul 21
 948 (10.1056/NEJMoa2108891).
- 949 96. A. Sheikh, J. McMenamin *et al.*, SARS-CoV-2 Delta VOC in Scotland: demographics, risk
 950 of hospital admission, and vaccine effectiveness. *Lancet* **397**, 2461-2462 (2021); published
 951 online EpubJun 26 (10.1016/S0140-6736(21)01358-1).
- 952 97. R. Wang, Q. Zhang et al., Analysis of SARS-CoV-2 variant mutations reveals neutralization 953 escape mechanisms and the ability to use ACE2 receptors from additional species. 954 Immunity 54. 1611-1621 e1615 (2021); published online EpubJul 13 955 (10.1016/j.immuni.2021.06.003).
- 956
 98. P. L. Shuo Du, Zhiying Zhang, Structures of SARS-CoV-2 B.1.351 neutralizing antibodies
 957 provide insights into cocktail design against concerning variants. *bioRxiv*,
 958 (2021)https://doi.org/10.1101/2021.07.30.454402).
- 959 99. M. Yuan, D. Huang *et al.*, Structural and functional ramifications of antigenic drift in recent
 960 SARS-CoV-2 variants. *Science*, (2021); published online EpubMay 20
 961 (10.1126/science.abh1139).
- 962 100. R. T. E. Chen, X. W. Zhang *et al.*, Resistance of SARS-CoV-2 variants to neutralization by
 963 monoclonal and serum-derived polyclonal antibodies. *Nature Medicine* 27, (2021);
 964 published online EpubApr (10.1038/s41591-021-01294-w).
- 965 101. D. K. Ryu, R. Song *et al.*, Therapeutic effect of CT-P59 against SARS-CoV-2 South African
 966 variant. *Biochem Biophys Res Commun* 566, 135-140 (2021); published online EpubAug
 967 20 (10.1016/j.bbrc.2021.06.016).
- 968102.P. Wang, R. G. Casner *et al.*, Increased resistance of SARS-CoV-2 variant P.1 to antibody969neutralization. *Cell Host Microbe* **29**, 747-751 e744 (2021); published online EpubMay 12970(10.1016/j.chom.2021.04.007).
- 971 103. D. Zhou, W. Dejnirattisai *et al.*, Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. *Cell* 184, 2348-2361 e2346 (2021); published online
 973 EpubApr 29 (10.1016/j.cell.2021.02.037).
- 974104.P. Supasa, D. Zhou *et al.*, Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by975convalescent and vaccine sera. *Cell* **184**, 2201-2211 e2207 (2021); published online976EpubApr 15 (10.1016/j.cell.2021.02.033).
- 977 105. X. Y. Shen, H. L. Tang et al., SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing

978 979 980 981 982 983 984 985 986 987 988	106. 107. 108.	 antibodies elicited by ancestral spike vaccines. <i>Cell Host & Microbe</i> 29, 529-+ (2021); published online EpubApr 14 (10.1016/j.chom.2021.03.002). D. R. Martinez, A. Schaefer <i>et al.</i>, A broadly neutralizing antibody protects against SARS-CoV, pre-emergent bat CoVs, and SARS-CoV-2 variants in mice. <i>bioRxiv</i>, (2021); published online EpubApr 28 (10.1101/2021.04.27.441655). D. A. Collier, A. De Marco <i>et al.</i>, Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. <i>Nature</i> 593, 136-141 (2021); published online EpubMay (10.1038/s41586-021-03412-7). R. E. Chen, E. S. Winkler <i>et al.</i>, In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. <i>Nature</i>, (2021); published online EpubJun 21 (10.1038/s41586-021-03720-y).
989		
990		
991		
992		
993		
994		
995		
996		
997		
998		
999		
1000		
1001		
1002		
1003		
1004		
1005		
1007		
1008		
1009		
1010		
1011		
1012		
1013		